Dong-A ST Reports Q2 Sales of 160.2 Billion KRW, Up 8.7% Year-on-Year
[Asia Economy Reporter Lee Gwan-ju] Dong-A ST announced on the 27th that it recorded sales of 160.2 billion KRW and an operating profit of 4.3 billion KRW in the second quarter of this year.
Second-quarter sales increased by 8.7% year-on-year as all sectors, including ETC (ethical drugs), overseas business, and medical devices & diagnostics, grew steadily. However, operating profit decreased by 45.1% due to increased selling and administrative expenses such as research and development (R&D) costs.
The ETC sector grew by 6.5% year-on-year due to increased sales of key products such as Motilitone, Grotropin, and Jubilia. The overseas business sector grew by 15% year-on-year as sales of Canbakkas (Cambodia) increased and sales of biopharmaceuticals such as Darbepoetin Alfa BS and Grotropin rose.
Additionally, the medical devices & diagnostics sector grew by 7.5% year-on-year due to increased sales of medical equipment such as endoscope washers and increased sales in the infection control area of the diagnostics sector.
In the R&D sector, the company plans to focus on the global development of the Stelara biosimilar 'DMB-3115.' Currently, Phase 3 clinical trials are underway in the United States and nine European countries, expected to be completed in the second half of this year. The diabetes treatment 'DA-1241' is preparing for global Phase 2 clinical trials.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Russian Foreign Ministry "Hopes for Visit by North Korean Foreign Minister Choe Son Hui This Year"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Moreover, the development of multiple new drugs is accelerating. The diabetes treatment 'DA-1229 (Sugannon)' is undergoing domestic Phase 2 clinical trials for the treatment of aortic valve calcification by the joint venture Redenvia and has initiated Phase 2b/3a clinical trials in the United States. The once-weekly patch-type dementia treatment 'DA-5207' has completed domestic Phase 1a trials and is currently in Phase 1b trials, while the overactive bladder treatment 'DA-8010' entered domestic Phase 3 clinical trials in March.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
